Heron Therapeutics Inc. Stock
€2.54
Your prediction
Heron Therapeutics Inc. Stock
Pros and Cons of Heron Therapeutics Inc. in the next few years
Pros
Cons
Performance of Heron Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Heron Therapeutics Inc. | -14.760% | -10.767% | -25.543% | 139.245% | 61.529% | -79.992% | - |
Ardelyx Inc. | -31.220% | -12.398% | -22.159% | 58.645% | -14.913% | -26.597% | - |
Evolus Inc | 3.550% | 5.155% | -13.559% | 58.140% | 12.707% | -2.857% | - |
Krystal Biotech | -1.590% | -1.928% | 12.140% | 53.102% | 42.543% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Heron Inc (HRTX) seems to be going through significant financial challenges. A closer inspection of the financial statements of the company shows declining assets, increasing liabilities, and persistent negative net income over the past few years. Despite being a part of the promising Biotechnology & Medical Research industry, Heron Inc's financial performance raises concerns about the company's growth and stability.
*Pros: *
Gross Profit Margin Improvement: Heron Inc has managed to improve its gross profit margin from approximately 42% in 2020 to around 49% in 2022. This suggests that it has been successful in controlling its cost of revenues and might be able to continue doing so in the future.
Comments